Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Mar 6;2024(3):rjae112.
doi: 10.1093/jscr/rjae112. eCollection 2024 Mar.

Unusual metastasis after radical cystectomy: case report

Mohammed H Mohammed  1 , Fadel Mardnly  1 , Mohamad Ghrer  1 , Louei Alia  1 , Lina W Assad  2
Affiliations
Case Reports

Unusual metastasis after radical cystectomy: case report

Mohammed H Mohammed et al. J Surg Case Rep. .

Abstract

Cutaneous metastasis of urothelial carcinoma after radical cystectomy is extremely rare. We present the case of a 57-year-old man who underwent a radical cystectomy with ileal conduit for the presence of a bladder tumor. He developed a cheek lesion after 2 months, which was diagnosed as a metastatic nodule along with bone metastases from high-grade bladder urothelial carcinoma. This nodule was treated with surgical removal with subsequent chemotherapy, but he succumbed after 10 months due to widespread metastatic disease.

Keywords: cheek metastasis; radical cystectomy; urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
CT showing a large bladder diverticulum on the posterior wall with a mass within it.
Figure 2
Figure 2
Microscopic examination showing neoplastic cells arranged in irregular nests invading the lamina propria and muscularis propria. Tumors cells showing nuclear pleomorphism, hyperchromasia, high N/C ratio with frequent mitotic figures.
Figure 3
Figure 3
Lymphovascular and neural invasion is seen.
Figure 4
Figure 4
Metastatic at left cheek.
Figure 5
Figure 5
PET-CT demonstrating an unclear, heterogeneous mass that leachates into the skin and adipose tissue underneath it and the left masticatory muscle measuring 40 × 20 mm showing pathological metabolic activity.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34. - PubMed
    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49. 10.3322/caac.21660. - DOI - PubMed
    1. Nadal R, Bellmunt J. Management of metastatic bladder cancer. Cancer Treat Rev 2019;76:10–21. - PubMed
    1. Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: result of large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068–77. - PubMed
    1. Alfred Witjes J, Lebret T, Comperat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2017;71:462–75. - PubMed

Publication types